Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Serologic Response of Nonimmune Subjects to Commercial Salk Vaccine: Response and Antibody Persistence with Four Doses

Serologic Response of Nonimmune Subjects to Commercial Salk Vaccine: Response and Antibody... Abstract In spite of the widespread use of killed poliomyelitis vaccine during the past 6 years, there are still relatively few data concerning the duration of immunity after a complete course of immunization. Thus, it is as yet not possible to give with assurance recommendations about the need for repeated doses of vaccine in order to maintain adequate protection. Salk1 has reported an excellent response to 3 doses of vaccine given according to his recommended regimen and reported that antibody to all 3 poliovirus types has persisted at a remarkably stable level for 6 years after the third dose. These most encouraging results are not representative of the experiences of others. However, it should be pointed out that the data of Salk on persistence were obtained from a small group of 13 children who were immunized with a vaccine of high potency that was especially prepared. The persistence of antibody References 1. Salk, J. E.: Persistence of Immunity After Administration of Formalin-Treated Poliovirus Vaccine , Lancet 2:715-723, 1960.Crossref 2. Brown, G. C., and Napier, J. A.: Serologic Status of Children 4 Years After Poliomyelitis Field Trial , J. Immun. 84:463-468, 1960. 3. Logan, J. S.; Field, A. M.; Macrae, A. D.; Miller, A., and Tobin, J. O.: Persistence of Antibody in Children After a Third Dose of Poliomyelitis Vaccine and Their Response to a Fourth , Brit. Med. J. 1:1692-1694, 1960.Crossref 4. Wolf, A. M.; Shaughnessy, H. J.; Janota, M.; Chapman, J. W.; Church, R. E., and Moore, M.: Duration of Seroimmunity After Injection with Ultraviolet-Irradiated Poliomyelitis Vaccine: Role of Booster Inoculations , J.A.M.A. 170:650-652, 1959.Crossref 5. Perkins, F. T.; Yetts, R., and Baisford, W.: Responses of 6- and 9-Months Old Infants to 2 and 3 Doses of Poliomyelitis Vaccine , Brit. Med. J. 2:530-532, 1959.Crossref 6. Salk, J. E.: How Many Injections of Poliomyelitis Vaccine for Effective and Durable Immunity? J.A.M.A. 167:1-7, 1958.Crossref 7. MacLeod, D. R.; Armstrong, C. W.; Moss, G. W.; Potter, F. C., and Wilson, R. J.: Poliovirus Antibody Response After Various Vaccination Schedules and at Different Ages , Canad. Med. Ass. J. 81:443-449, 1959. 8. Batson, R.; Christie, A.; Turner, D.; Michal, M., and Barrick, J. H.: The Persistence of Poliomyelitis Antibodies After Primary Immunization of Young Infants , Pediatrics 23:550-552, 1959. 9. Perkins, F. T.; Yetts, R., and Gaisford, W.: Serological Response of Infants to Poliomyelitis Vaccine, Brit. Med. J. 2:68-71, 1958.Crossref 10. Brown, G. C., and Kendrick, P. L.: Serologic Response of Infants to a Multiple Vaccine for Simultaneous Immunization Against Diphtheria, Pertussis, Tetanus, and Poliomyelitis in Relation to the Presence of Specific Maternal Antibody, Amer. J. Public Health 50:1529-1538, 1960.Crossref 11. Brown, G. C., and Smith, D. C.: Serologic Response of Infants and Preschool Children to Poliomyelitis Vaccine , J.A.M.A. 161:399-403, 1956.Crossref 12. Gelfand, H. M.; LeBlanc, D. R.; Fox, J. P., and Potash, L.: Studies on Development of Natural Immunity to Poliomyelitis in Louisiana: III. Serologic Response to Commercially Produced "Salk Vaccine" of Children Totally or Partially Susceptible to Poliovirus Infection , Amer. J. Hyg. 70:303-311, 1959. 13. Shaughnessy, H. J.; Morrissey, R. A.; Church, R. E., and Neal, J.: Antibody Responses to Commercial Poliomyelitis Vaccines in Young Children, Abstract , Amer. J. Public Health 47:613, 1957.Crossref 14. Sunada, K.; Gerloff, R. K.; Brock, D.; Hopkey, I.; Eklund, C. M., and Klotz, A. W.: Observations on the Potency and Safety of Poliomyelitis Vaccine (Salk Type) Currently Used , A.M.A. J. Dis. Child. 96:125-130, 1958. 15. Perkins, F. T.; Yetts, R., and Gaisford, W.: Poliomyelitis Immunization in Infants in the Presence of Maternally Transmitted Antibody , Brit. Med. J. 1:404-406, 1961.Crossref 16. Berkovich, S.; Pickering, J. E., and Kibrick, S.: Paralytic Poliomyelitis in Massachusetts, 1959: A Study of the Disease in a Well-Vaccinated Population , New Engl. J. Med. 264:1323-1329, 1961.Crossref 17. Murray, R.: Standardization, Licensing and Availability of Live Poliovirus Vaccine , J.A.M.A. 175:843-846, 1961.Crossref 18. Reference deleted. 19. Kokko, U. P., and Murray, R.: Human and Animal Antibody Responses to Commercial Poliomyelitis Vaccine , Bull. WHO 22:263-272, 1960. 20. Salk, J. E.; Youngner, J. S., and Ward, E. N.: Use of Color Change of Phenol Red as Indicator in Titrating Poliomyelitis Virus or Its Antibody in a Tissue-Culture System , Amer. J. Hyg. 60:214-230, 1954. 21. Hammon, W. M.: Passive Immunization Against Poliomyelitis with Especial Consideration of the Effectiveness of Gamma Globulin , Bull. N.Y. Acad. Med. 29:930-942, 1953. 22. Bodian, D.: Experimental Studies on Passive Immunization Against Poliomyelitis: II. The Prophylactic Effect of Human Gamma Globulin on Paralytic Poliomyelitis in Cynomolgus Monkeys After Virus Feeding , Amer. J. Hyg. 56:78-89, 1952. 23. Bodian, D.: Pathogenesis of Poliomyelitis, Donald M. Gudakunst Memorial Lecture , Amer. J. Public Health 42:1388-1402, 1952.Crossref 24. Sabin, A. B.: Properties of Attenuated Polioviruses and Their Behavior in Human Beings , Special Publications, N.Y. Acad. Sci. 5:113-127, 1957. 25. Weihl, C.; Cornfeld, D.; Riley, H. D.; Huang, N., and Cramblett, H.: Purified Poliomyelitis Vaccine: Clinical Appraisal , J.A.M.A. 176: 409-412, 1961.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Diseases of Children American Medical Association

Serologic Response of Nonimmune Subjects to Commercial Salk Vaccine: Response and Antibody Persistence with Four Doses

Download PDF
9 pages

Loading next page...
 
/lp/american-medical-association/serologic-response-of-nonimmune-subjects-to-commercial-salk-vaccine-cku0d80cVB

References (25)

Publisher
American Medical Association
Copyright
Copyright © 1962 American Medical Association. All Rights Reserved.
ISSN
0002-922X
DOI
10.1001/archpedi.1962.02080020820010
Publisher site
See Article on Publisher Site

Abstract

Abstract In spite of the widespread use of killed poliomyelitis vaccine during the past 6 years, there are still relatively few data concerning the duration of immunity after a complete course of immunization. Thus, it is as yet not possible to give with assurance recommendations about the need for repeated doses of vaccine in order to maintain adequate protection. Salk1 has reported an excellent response to 3 doses of vaccine given according to his recommended regimen and reported that antibody to all 3 poliovirus types has persisted at a remarkably stable level for 6 years after the third dose. These most encouraging results are not representative of the experiences of others. However, it should be pointed out that the data of Salk on persistence were obtained from a small group of 13 children who were immunized with a vaccine of high potency that was especially prepared. The persistence of antibody References 1. Salk, J. E.: Persistence of Immunity After Administration of Formalin-Treated Poliovirus Vaccine , Lancet 2:715-723, 1960.Crossref 2. Brown, G. C., and Napier, J. A.: Serologic Status of Children 4 Years After Poliomyelitis Field Trial , J. Immun. 84:463-468, 1960. 3. Logan, J. S.; Field, A. M.; Macrae, A. D.; Miller, A., and Tobin, J. O.: Persistence of Antibody in Children After a Third Dose of Poliomyelitis Vaccine and Their Response to a Fourth , Brit. Med. J. 1:1692-1694, 1960.Crossref 4. Wolf, A. M.; Shaughnessy, H. J.; Janota, M.; Chapman, J. W.; Church, R. E., and Moore, M.: Duration of Seroimmunity After Injection with Ultraviolet-Irradiated Poliomyelitis Vaccine: Role of Booster Inoculations , J.A.M.A. 170:650-652, 1959.Crossref 5. Perkins, F. T.; Yetts, R., and Baisford, W.: Responses of 6- and 9-Months Old Infants to 2 and 3 Doses of Poliomyelitis Vaccine , Brit. Med. J. 2:530-532, 1959.Crossref 6. Salk, J. E.: How Many Injections of Poliomyelitis Vaccine for Effective and Durable Immunity? J.A.M.A. 167:1-7, 1958.Crossref 7. MacLeod, D. R.; Armstrong, C. W.; Moss, G. W.; Potter, F. C., and Wilson, R. J.: Poliovirus Antibody Response After Various Vaccination Schedules and at Different Ages , Canad. Med. Ass. J. 81:443-449, 1959. 8. Batson, R.; Christie, A.; Turner, D.; Michal, M., and Barrick, J. H.: The Persistence of Poliomyelitis Antibodies After Primary Immunization of Young Infants , Pediatrics 23:550-552, 1959. 9. Perkins, F. T.; Yetts, R., and Gaisford, W.: Serological Response of Infants to Poliomyelitis Vaccine, Brit. Med. J. 2:68-71, 1958.Crossref 10. Brown, G. C., and Kendrick, P. L.: Serologic Response of Infants to a Multiple Vaccine for Simultaneous Immunization Against Diphtheria, Pertussis, Tetanus, and Poliomyelitis in Relation to the Presence of Specific Maternal Antibody, Amer. J. Public Health 50:1529-1538, 1960.Crossref 11. Brown, G. C., and Smith, D. C.: Serologic Response of Infants and Preschool Children to Poliomyelitis Vaccine , J.A.M.A. 161:399-403, 1956.Crossref 12. Gelfand, H. M.; LeBlanc, D. R.; Fox, J. P., and Potash, L.: Studies on Development of Natural Immunity to Poliomyelitis in Louisiana: III. Serologic Response to Commercially Produced "Salk Vaccine" of Children Totally or Partially Susceptible to Poliovirus Infection , Amer. J. Hyg. 70:303-311, 1959. 13. Shaughnessy, H. J.; Morrissey, R. A.; Church, R. E., and Neal, J.: Antibody Responses to Commercial Poliomyelitis Vaccines in Young Children, Abstract , Amer. J. Public Health 47:613, 1957.Crossref 14. Sunada, K.; Gerloff, R. K.; Brock, D.; Hopkey, I.; Eklund, C. M., and Klotz, A. W.: Observations on the Potency and Safety of Poliomyelitis Vaccine (Salk Type) Currently Used , A.M.A. J. Dis. Child. 96:125-130, 1958. 15. Perkins, F. T.; Yetts, R., and Gaisford, W.: Poliomyelitis Immunization in Infants in the Presence of Maternally Transmitted Antibody , Brit. Med. J. 1:404-406, 1961.Crossref 16. Berkovich, S.; Pickering, J. E., and Kibrick, S.: Paralytic Poliomyelitis in Massachusetts, 1959: A Study of the Disease in a Well-Vaccinated Population , New Engl. J. Med. 264:1323-1329, 1961.Crossref 17. Murray, R.: Standardization, Licensing and Availability of Live Poliovirus Vaccine , J.A.M.A. 175:843-846, 1961.Crossref 18. Reference deleted. 19. Kokko, U. P., and Murray, R.: Human and Animal Antibody Responses to Commercial Poliomyelitis Vaccine , Bull. WHO 22:263-272, 1960. 20. Salk, J. E.; Youngner, J. S., and Ward, E. N.: Use of Color Change of Phenol Red as Indicator in Titrating Poliomyelitis Virus or Its Antibody in a Tissue-Culture System , Amer. J. Hyg. 60:214-230, 1954. 21. Hammon, W. M.: Passive Immunization Against Poliomyelitis with Especial Consideration of the Effectiveness of Gamma Globulin , Bull. N.Y. Acad. Med. 29:930-942, 1953. 22. Bodian, D.: Experimental Studies on Passive Immunization Against Poliomyelitis: II. The Prophylactic Effect of Human Gamma Globulin on Paralytic Poliomyelitis in Cynomolgus Monkeys After Virus Feeding , Amer. J. Hyg. 56:78-89, 1952. 23. Bodian, D.: Pathogenesis of Poliomyelitis, Donald M. Gudakunst Memorial Lecture , Amer. J. Public Health 42:1388-1402, 1952.Crossref 24. Sabin, A. B.: Properties of Attenuated Polioviruses and Their Behavior in Human Beings , Special Publications, N.Y. Acad. Sci. 5:113-127, 1957. 25. Weihl, C.; Cornfeld, D.; Riley, H. D.; Huang, N., and Cramblett, H.: Purified Poliomyelitis Vaccine: Clinical Appraisal , J.A.M.A. 176: 409-412, 1961.Crossref

Journal

American Journal of Diseases of Children – American Medical Association

Published: Jun 1, 1962

There are no references for this article.